All News

The median time to PSA0.2 was 3.5 months in the apalutamide group, 4.4 months in the enzalutamide cohort, and 7.1 months in the abiraterone acetate group.

The deep PSA responses with the darolutamide regimen were found to be correlated with improved overall survival and a prolonged time to PSA progression.

The overall survival benefit of darolutamide in the North American population as a whole was also specifically observed in Black/African American patients.

Irrespective of response to first-line platinum-based chemotherapy, frontline maintenance therapy with avelumab plus best supportive care (BSC), compared with BSC alone, prolonged overall and progression-free survival in patients with advanced urothelial carcinoma.

“The benefits of FAP-PET imaging include the higher specificity compared to conventional imaging. There's also the potential for upstaging,” said Domenique Escobar, MD.

"Patients with a prior BPH procedure were on average older than our HoLEP controls; however, there were no other differences in preoperative patient characteristics or postoperative functional outcomes," said Nicholas S. Dean, MD.

"Dose reduction for patients with small body size may alleviate skin AEs without sacrificing oncological outcomes,” said Kyo Togashi.

Clinical progression-free survival following the first cycle of radioligand therapy was 6.3 months, and overall survival following the first cycle was 21.4 months.

A database analysis of patients who participated in the STAMPEDE trial showed that zoledronic acid can significantly lower the risk of fracture in patients with with metastatic hormone-sensitive prostate cancer starting long-term ADT.

The study is exploring the investigational N-terminal domain androgen receptor inhibitor EPI-7386 in combination with either apalutamide or abiraterone acetate.

“I think we really hit upon how we work closely together in renal cell cancer—urothelial cancers in particular,” says Joelle Hamilton, MD.

"Men's health, as a sort of separate discipline or a sub discipline within urology, is definitely growing," says Andrew Y. Sun, MD.

The guideline updates span non-metastatic upper tract urothelial carcinoma, female stress urinary incontinence, urethral stricture disease, and prostate cancer.

Roger Li, MD, highlights 4 studies in bladder cancer being presented at the 2023 American Urological Association Annual Meeting.

"This is something [that is] a lot easier for the patient, it's a lot less costly to the health care system to stay out of the operating room, and it's a lot quicker for me," says Howard B. Goldman, MD.

Physicians are now using the AI-powered Unfold AI platform to work with patients on treatment selection and establishing an optimal overall management plan.

“Our results indicate that avoiding unhealthy dietary habits could be the best nutritional strategy to prevent aggressive prostate cancer,” says Adela Castelló-Pastor, PhD.

“I think being savvy about how you deal with BCG supply on the administrative side is important,” says Suzanne B. Merrill, MD, FACS.

The designation is for patients with mCRPC who have progressed on an androgen receptor pathway inhibitor and are not eligible for or decline to receive chemotherapy.

"At the end [of my talk], I really wanted to focus on how Specialty Networks could partner with us," says Jannah H. Thompson, MD, FPMRS.

This marks the first worldwide approval for the niraparib/abiraterone dual-action tablet.

“There is a growing consensus that a hard medical liability insurance market exists in a considerable number of states and is slowly spreading across the United States as more physicians face higher insurance premiums,” said AMA President Jack Resneck Jr., MD.

Melissa A. Laudano, MD, highlights 3 studies in overactive bladder/incontinence being presented at the 2023 American Urological Association Annual Meeting.

The tool uses a tumor-to-salivary gland ratio (PSG score) to predict outcomes.

Helen L. Bernie, DO, MPH, highlights 4 studies in sexual dysfunction being presented at the 2023 American Urological Association Annual Meeting.

"Our findings underscore the commercial and market factors that have been influencing bladder cancer care," says Brian Chun, MD.

Michael S. Cookson, MD, MMHC, highlights 5 studies in prostate cancer being presented at the 2023 American Urological Association Annual Meeting.

Shilpa Gupta, MD, shares her expert insight on the evolving treatment paradigm for patients with muscle-invasive bladder cancer, along with obstacles that must be overcome to further advance the field.

TLX250-CDx PET/CT demonstrated a high degree of sensitivity (85.5%) and specificity (87.0%) for detection of clear cell renal cell carcinoma in patients with indeterminate renal masses.

"Although payers are supposed to adopt CPT instructions, we unfortunately do not have a system that contractually binds payers to follow CPT instructions verbatim," write Jonathan Rubenstein, MD, and Mark Painter.